Related Experiment Videos
[Regulatory framework of cell therapy products]
Saliha Moussaoui1, Sophie Lucas, Pierette Zorzi
1Direction de l'évaluation des produits biologiques, Agence française de sécuriré sanitaire des produits de santé, 143-147, boulevard Anatole-France, 93285 Saint-Denis, France.
Bulletin Du Cancer
|November 12, 2003
Summary
Cell therapy, the use of cells to treat disease, requires regulation due to safety and ethical concerns. France has established a framework, but a unified European regulation is needed for cell-based products.
Area of Science:
- Cell therapy involves the in vivo application of autologous, allogeneic, or xenogeneic cells for disease prevention, treatment, or attenuation.
Context:
- Recent advancements in cell therapy have led to numerous clinical applications.
- Safety and ethical considerations necessitate the regulation of therapeutic cell products.
- France has implemented specific laws (96-452, 98-535) establishing a regulatory framework for cell therapy products.
Purpose:
- To outline the regulatory landscape for cell therapy products in France.
- To highlight the need for a harmonized European regulatory approach for cell-based products.
Summary:
- Therapeutic cell products in France require prior authorization for preparation sites and clinical trials, granted by the French Health Products Agency (Afssaps).
- Depending on their classification, products may be authorized by Afssaps or the European Agency for the Evaluation of Medicinal Products (EMEA).
- Quality, security, and therapeutic validation are essential for all cell therapy products, regardless of their regulatory status.
Impact:
- The current regulation of cell-based products varies across European member states.
- A unified European regulation is crucial for consistent oversight and to facilitate the broader adoption of cell therapies.